Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-06-04 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司审计委员会实施细则（2025年6月）
Governance Information Classification · 95% confidence The document is titled '审计委员会实施细则' which translates to 'Audit Committee Implementation Rules'. It details the structure, responsibilities, and procedures of the company's audit committee, including oversight of financial reporting, internal and external audits, and internal controls. It does not contain actual financial statements or financial performance data. Instead, it is a governance document outlining audit committee rules and functions. This fits the category of Governance Information (CGR), which covers reports detailing internal rules, board structure, and governance practices. The document length is 3193 characters, and it is a detailed policy document rather than an announcement or a report with financial data. Therefore, the appropriate classification is CGR with high confidence.
2025-06-04 Chinese
江苏四环生物股份有限公司公司董事会议事规则（2025年6月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors' of Jiangsu Sihuan Bio Co., Ltd. It details the composition, responsibilities, meeting procedures, voting rules, and record-keeping of the company's board of directors. There are no financial statements, audit opinions, or financial results presented. The document is a governance-related internal rules document, not a report or announcement of financial results or corporate actions. It is a detailed governance information document outlining the board's operational rules and procedures. Therefore, the appropriate classification is Governance Information (CGR). The document length (8715 characters) supports it being a full governance document rather than a brief announcement.
2025-06-04 Chinese
江苏四环生物股份有限公司关于变更注册地址并修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from 江苏四环生物股份有限公司 regarding the change of the company's registered address and the revision of the company's articles of association (公司章程). It includes extensive text about the amendments to the articles, governance structure changes, shareholder rights, board responsibilities, and other corporate governance matters. There is no indication of financial statements, audit opinions, earnings data, or other financial report content. The document is not a report itself but an official announcement of corporate governance changes and related resolutions. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-06-04 Chinese
江苏四环生物股份有限公司2024年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It includes voting results on various proposals such as the 2024 annual report, board work report, financial statements, profit distribution plan, and remuneration plans. It also mentions the meeting date, attendance, voting methods, and legal opinions on the meeting's validity. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. The length is about 4436 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-21 Chinese
江苏四环生物股份有限公司2024年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2024 Annual General Meeting (AGM) of Jiangsu Sihuan Pharmaceutical Co., Ltd. It discusses the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but rather confirms the proper conduct and legality of the AGM and its resolutions. The document length is 2622 characters, which is relatively short and consistent with a legal opinion or meeting-related announcement rather than a full report. Therefore, this document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and announcement of the AGM voting results and procedures.
2025-05-21 Chinese
江苏四环生物股份有限公司关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders for Jiangsu Sihuan Bioengineering Co., Ltd. It details the meeting date, voting methods, agenda items (such as election of board directors), registration procedures, and voting instructions. It does not contain financial statements or results, nor is it a transcript or report of the meeting outcomes. The document is an announcement informing shareholders about the upcoming meeting and how to participate. Given the content and length (3500 characters), it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-05-16 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.